Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Multi Centers, Phase II Study of Sintilimab, Doxorubicin and Ifosfamide at First-line Treatment of Soft Tissue Sarcoma Including Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, Myxoid Liposarcoma and De-differentiated Liposarcoma

Next Previous
Trial Profile

A Single Arm, Multi Centers, Phase II Study of Sintilimab, Doxorubicin and Ifosfamide at First-line Treatment of Soft Tissue Sarcoma Including Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, Myxoid Liposarcoma and De-differentiated Liposarcoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Doxorubicin; Ifosfamide
  • Indications Liposarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Primary endpoint (overall response rate, ORR) has been met.
  • 04 Jun 2024 Results (n=46) assessing the safety and activity of sintilimab, an anti-PD-1 antibody, combined with doxorubicin (ADM) and ifosfamide (IFO) in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS) were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 27 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top